Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M1 positive allosteric modulator (Asceneuron)
- Development stage
- Preclinical
- Lead developer
- Asceneuron
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The M1 positive allosteric modulator (including the lead compound ASN-408) is a small molecule drug being developed by Asceneuron to treat cognitive deficits in neurodegenerative conditions such as Parkinson's disease dementia (PDD), Lewy Body Dementia (LBD), and Frontotemporal dementia (FTD). It functions by binding to an allosteric site on the M1 muscarinic acetylcholine receptor (M1 mAChR), which enhances the receptor's affinity for its natural ligand, acetylcholine. This mechanism potentiates cholinergic signaling specifically at the M1 subtype—a target critical for memory and executive function—while avoiding the adverse side effects typically caused by non-selective activation of other muscarinic receptor subtypes (M2-M5). The compound has shown high specificity and nanomolar potency in cellular assays and neuronal cultures.
- Other names
- Asceneuron M1 positive allosteric modulator
02
Targets
M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on M1 positive allosteric modulator (Asceneuron).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M1 positive allosteric modulator (Asceneuron).